5th Circ. Affirms Brand, Generic Wins In Reglan Suits

Law360, New York (February 21, 2014, 7:02 PM EST) -- The Fifth Circuit on Friday upheld victories for brand-name and generic makers of the heartburn drug Reglan in two personal injury lawsuits, rejecting the plaintiffs' assertion that their claims against the generic makers are not preempted because they parallel federal law.

In a nonprecedential opinion, the appeals court affirmed the dismissal of claims against generic manufacturers Watson Pharma Inc., Watson Laboratories Inc., Teva Pharmaceuticals USA Inc., Pliva Inc. and Vintage Pharmaceuticals LLC and the granting of summary judgment in favor of Pfizer Inc., Wyeth Inc. and...
To view the full article, register now.